Acurian Appoints Shannon Yung as Newest Clinical Trial Liaison for Its Cancer Enrollment Support Service

HORSHAM, Pa.--(BUSINESS WIRE)-- Acurian, Inc., a leading, full-service provider of global patient recruitment and retention solutions, announced today the appointment of Shannon L. Yung as its newest Clinical Trial Liaison (CTL) team member. She joins a group dedicated to providing specialized, localized and personalized service for oncology trial patient enrollment.

Acurian created its CTL offering based on extensive research that found most local physicians and advocacy groups are interested in cancer research as a patient option, but need on-site education and awareness to better understand trial opportunities. Yung, based in St. Louis, MO, will actively engage physicians, advocacy groups and other stakeholders in a discussion of the science behind a sponsor’s specific clinical study being conducted at a local trial site.

As a registered nurse with more than 12 years of experience, Shannon was most recently a Clinical Nurse Liaison for the Oncology Business Unit at Amgen, located in Thousand Oaks, CA. There she handled the responsibilities of managing the unit’s oncology products, territory management, and training nurse speakers.

Career highlights include positions at Innovex for Bristol-Myers Squibb and Barnes Jewish Health Systems. Yung was educated at Southwestern Illinois College, Lutheran Medical Center School of Nursing, McKendree College, and McKendree University.

“We’re extremely pleased to have Shannon join our growing CTL team,” said Edwin Watson, Director, Oncology Services at Acurian. “She is exactly the type of oncology professional that defines Acurian’s goal of placing more team members just like her in a number of strategic geographic areas around the country.”

About Acurian

Acurian is a leading full-service provider of clinical trial patient recruitment and retention solutions for the life sciences industry. Through its proprietary patient panel of over 65 million patients, centralized advertising capabilities, and a fully hosted enrollment management technology platform, Acurian is able to identify, contact, prescreen, and refer patients into clinical trials across the globe, all while supporting investigator sites with services to maximize the randomization potential of every referred patient. Since 1998, Acurian has supported over 400 protocols for more than 60 companies. Acurian's investors include Euclid SR Partners, ProQuest Investments, JP Morgan Partners, Flatiron Partners, CDP Capital Technology Ventures, and Merck Capital Ventures.



CONTACT:

Acurian, Inc.
Scott Connor, Vice President, Marketing, 215-323-9028
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.